South Korea Palm Oil Market Size, Share, and COVID-19 Impact Analysis, By Type (Exocrine and Endocrine), By Treatment (Chemotherapy, Radiation Therapy, and Others), and South Korea Pancreatic Cancer Treatment Market Insights, Industry Trend, Forecasts to 2035

South Korea Pancreatic Cancer Treatment Market Insights Forecasts to 2035

• The South Korea Pancreatic Cancer Treatment Market Size Was Estimated at USD 61.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 12.80% from 2025 to 2035
• The South Korea Pancreatic Cancer Treatment Market Size is Expected to Reach USD 231.7 Million by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Pancreatic Cancer Treatment Market is anticipated to reach USD 231.7 Million by 2035, Growing at a CAGR of 12.80% from 2025 to 2035. The south Korea pancreatic cancer treatment market is driven by rising incidence of pancreatic cancer due to aging populations and lifestyle changes, rising awareness, and advancements in diagnostic imaging.  

Market Overview

Pancreatic cancer treatment refers to the medical techniques and medicines used to manage, control, or cure pancreatic cancer, which is a malignant tumor of the pancreas. The South Korean pancreatic cancer treatment refers to the development, production, distribution, and commercializing of therapies and medical solutions for pancreatic cancer. This market includes surgical procedures, chemotherapy, radiation therapy, immunotherapy, and palliative care. The rising incidence of pancreatic cancer to various factors, such as an aging population, lifestyle changes, obesity, smoking, and genetic predisposition drive the demand for effective treatments. Rising demand for minimally invasive surgery is a key trend, with laparoscopic and robotics-assisted treatments increasingly prevalent in South Korea to minimize recovery time and complications for pancreatic cancer patients. The rise of targeted therapies, immunotherapies, and personalized medicine offers an opportunity for pharmaceutical and biotech businesses to create novel pancreatic cancer treatments in South Korea.

Report Coverage

This research report categorizes the market for the south Korea pancreatic cancer treatment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the south Korea pancreatic cancer treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the south Korea pancreatic cancer treatment market.

Driving Factors

The South Korean pancreatic cancer treatment is witnessing robust growth, driven by several critical factors. One of the major drivers for this market is the rising incidence of pancreatic cancer in South Korea. As pancreatic cancer remains one of the most aggressive and lethal cancers, there is an increasing desire for effective and sophisticated therapies. Advancements in diagnostics have also significantly contributed to the market expansion. Additionally, the development of innovative therapies such as targeted therapeutics, immunotherapy, and personalized medicine fuels the market growth.

Restraining Factors

One of the major challenges is the high cost of treatments, including surgery, chemotherapy, targeted therapy and immunotherapy, which limit patient access, especially for those without complete insurance coverage. Additionally, strict regulations led to complexity and product delay, further hindering the market growth.

Market Segmentation

The South Korea pancreatic cancer treatment market share is classified into type and treatment.

• The exocrine segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea pancreatic cancer treatment market is segmented by type into exocrine and endocrine. Among these, the exocrine segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is the most common type of disorder of the pancreas and is linked to risk factors such as diabetes, gastrointestinal surgery, and cystic fibrosis. Furthermore, chronic pancreatitis is becoming more common, and lifestyle habits such as excessive sugar and alcohol use play a key role in its occurrence.

• The chemotherapy segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The south Korea pancreatic cancer treatment market is segmented by treatment into chemotherapy, radiation therapy, and others. Among these, the chemotherapy segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment's growth is being driven by factors such as the rising frequency of pancreatic cancer, advances in chemotherapeutic medication development, and increased research activities in the sector.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the south Korea Pancreatic Cancer Treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Amgen
• Merck
• AstraZeneca
• Roche
• Pfizer
• Hanmi Pharmaceutical
• SK Life Science
• IMage Guided Therapy (IMGT) Co., Ltd.
• PharmAbcine

Recent Development

• In January 2025, South Korea’s GI Innovation signed an MOU with LaNova Medicines to develop a combination pancreatic cancer therapy, GI-102 and LM-302, showing promising preclinical anticancer activity

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the U.S., regional, and country levels from 2020 to 2035. Spherical Insights has segmented the south Korea pancreatic cancer treatment market based on the below-mentioned segments:

South Korea Pancreatic Cancer Treatment Market, By Type

• Exocrine
• Endocrine

South Korea Pancreatic Cancer Treatment Market, By Treatment

• Chemotherapy
• Radiation Therapy
• Others